$IPSC

Carr Douglas sold $544 of IPSC

Carr Douglas (SVP Finance & Operations) sold 275 shares of Century Therapeutics, Inc. (IPSC) at $1.98 on 2026-08-03.

Original reporting
SEC EDGAR · Carr Douglas
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IPSC
Neutral
medium confidence
Mentioned
$IPSC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

An officer-level open-market sale was reported without a stated 10b5-1 plan; however, the dollar value is modest and does not include any company performance or guidance change.

02

Market read

Traders may briefly monitor for sentiment around insider selling, but the filing lacks new fundamental catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, but the article provides no additional context (e.g., tax, planned spending, or other concurrent transactions).

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

This is an SEC Form 4 insider transaction disclosure for Century Therapeutics, Inc. (IPSC).

Company-level read

Ticker impact

$IPSCNeutralMedium confidence
Context

Century Therapeutics (IPSC) disclosed an SVP Finance & Operations open-market sale of 275 shares at $1.9770 on 2026-08-03.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

Form 4 shows a direct open-market sale (code S) totaling about $543.68, with holdings after transaction at 504,819 shares. No new operational, regulatory, or financial guidance is provided.

Market effects

No sector-level implications; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is small relative to post-transaction holdings, it may reflect diversification or liquidity needs rather than negative expectations.

Key entities

  • Century Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Carr Douglas

    SVP Finance & Operations who sold 275 shares.

Related articles

$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

$IPSCMedAI 8/10

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa